{
    "clinical_study": {
        "@rank": "57067", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "SP2086 50 mg b.i.d", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "SP2086 100 mg q.d.", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the\n      efficacy and safety of SP2086 as monotherapy  in patients with Type 2 Diabetes Mellitus in\n      Metformin monotherapy Who Have Inadequate Glycemic Control treated with  diet and exercise\n      for 3 months"
        }, 
        "brief_title": "Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with type 2 diabetes mellitus\n\n          -  Patients have treated with diet/exercise at least 3 months\n\n          -  7.5% \u2264HbA1C \u226411.0% at screening,7.0% \u2264HbA1C \u226410.5% after run-in\n\n        Exclusion Criteria:\n\n          -  Patient has history of type 1 diabetes mellitus\n\n          -  Patient has history of ketoacidosis\n\n          -  Patient has history of severe unconscious hypoglycemosis\n\n          -  Patient has history of acute and chronic pancreatitis or pancreatic injury that may\n             lead to high risk of pancreatitis\n\n          -  Patient has history of decompensated heart failure (NYHA class III and IV), unstable\n             angina, stroke or transient ischemic attack, myocardial infarction, persistence and\n             clinical\n\n          -  Patient has history of a history of hypertension, and after antihypertensive\n             treatment, systolic blood pressure \u2265 160 mmHg or diastolic blood pressure \u2265 100 mmHg\n\n          -  Patient has severe liver or kidney disease,alanine aminotransferase >2\u00d7UNL, Aspartate\n             Aminotransferase >2\u00d7upper normal limit(UNL)\uff1btotal bilirubin >2\u00d7UNL\uff1b creatinine>1.5\n             mg/dL (Male,132.6\u03bcmol/L) \uff0c>1.4 mg/dL(Female\uff0c123.8\u03bcmol/L)\n\n          -  Patient has severe chronic gastrointestinal disease or therapy that may affect drug\n             absorption, such as gastrointestinal surgery\n\n          -  Patient has severe haematological diseases or other diseases leading to hemolyze and\n             red blood cell unstable (malaria\u3001haemolytic anaemia eg. )\n\n          -  Patient has other endocrine diseases, for example\n             hyperthyroidism\u3001hypothyroidism\u3001hypercortisolism\u3001multiple endocrine neoplasia and so\n             on\n\n          -  Patient has history of malignancy\n\n          -  Patient has history of alcohol or drug abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970033", 
            "org_study_id": "HR-SP2086-301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Run in period \uff1aoral tablets of Placebo twice daily for 2 weeks\nPhase A : oral tablets of Placebo twice daily for 24 weeks\nPhase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SP2086 50 mg b.i.d", 
                "description": "Run-in period: placebo twice daily for 2 weeks\nPhase A:SP2086 50 mg b.i.d for 24 weeks\nPhase B:SP2086 50 mg b.i.d for 28 weeks", 
                "intervention_name": "SP2086 50 mg b.i.d.", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SP2086 100 mg q.d.", 
                "description": "Run-in period:placebo twice daily for 2 weeks\nPhase A: SP2086 100 mg q.d. for 24 weeks\nPhase B: SP2086 100 mg q.d. for 28 weeks", 
                "intervention_name": "SP2086 100 mg q.d.", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "SP2086", 
            "Phase III", 
            "Monotherapy"
        ], 
        "lastchanged_date": "October 22, 2013", 
        "location": {
            "contact": {
                "email": "panchy301@aliyun.com", 
                "last_name": "Changyu Pan, M.D."
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Chinese PLA General Hospital"
            }, 
            "investigator": {
                "last_name": "Changyu Pan, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase III Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients", 
        "overall_contact": {
            "email": "panchy301@aliyun.com", 
            "last_name": "Changyu Pan, M.D.", 
            "phone": "86 10 66887329"
        }, 
        "overall_contact_backup": {
            "email": "shenhuaqiong@hrs.com.cn", 
            "last_name": "Huaqiong Shen, P.H.D", 
            "phone": "86 21 68868570", 
            "phone_ext": "827"
        }, 
        "overall_official": {
            "affiliation": "Chinese PLA General Hospital", 
            "last_name": "Changyu Pan, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent", 
            "measure": "Change From Baseline in HbA1c (Hemoglobin A1C) at Week24", 
            "safety_issue": "No", 
            "time_frame": "baseline, week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970033"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG", 
                "measure": "Change From Baseline in fasting plasma glucose (FPG) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-24"
            }, 
            {
                "description": "Change from baseline at Week 24 is defined as Week 24 2-hr PMG minus Week 0 2-hr PMG", 
                "measure": "Change From Baseline in 2-hour Post-meal Glucose (2-hr PMG) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-24"
            }, 
            {
                "measure": "Percentage of Participants Achieving Less Than (<) 6.5% or <7% HbA1c Levels", 
                "safety_issue": "No", 
                "time_frame": "week24"
            }, 
            {
                "description": "A1C is measured as a percent. Thus, this change from baseline reflects the Week 52 A1C percent minus the Week 0 A1C percent", 
                "measure": "Change From Baseline in A1C at Week 52", 
                "safety_issue": "No", 
                "time_frame": "week 52"
            }, 
            {
                "description": "Change from baseline at Week 52 is defined as Week 104 FPG minus Week 0 FPG", 
                "measure": "Change From Baseline in FPG at Week 52", 
                "safety_issue": "No", 
                "time_frame": "week 52"
            }, 
            {
                "measure": "Change From Baseline in lipid at Week 4\u30018\u300112\u300124\u300138\u300152", 
                "safety_issue": "No", 
                "time_frame": "Week 4\u30018\u300112\u300124\u300138\u300152"
            }, 
            {
                "measure": "Change From Baseline in Body Weight at Week 4,8,12\u300124\u300138\u300152", 
                "safety_issue": "No", 
                "time_frame": "Week 4\u30018\u300112\u300124\u300138\u300152"
            }
        ], 
        "source": "Jiangsu HengRui Medicine Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu HengRui Medicine Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}